Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HOOKIPA Pharma Inc. (HOOK)
USD1.15
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
350 Fifth Avenue 10118
New York, NY, US
New York, NY, US
CEO
Malte Peters
Website
hookipapharma.com
IPO
2019-04-18
CIK 1760542 ISIN US43906K2096
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.15
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
12.0K
Beta
0.77
Float Shares
9.49M
Free Float %
75.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +3.51% | +14.56% | +34.98% | +32.14% | -11.94% | -93.95% | -99.29% | -99.16% | -99.16% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
1.15
Low
3.00
+160.9%
Consensus
3.00
+160.9%
Median
3.00
+160.9%
High
3.00
+160.9%
Ratings Trend (MoM)
0% Bullish
| Rating | 2025-08 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
3.00
+160.9%
|
Quality scores
Altman Z-Score
-13.41
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-77.9% Q2'25: +426.7% (vs Q2'24)
-
EPS growth Biotechnology: +29.7%+68.6% ★ Q2'25: +73.7% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-311.3% Q2'25: -105.0% (vs Q2'24)
-
EBIT margin Biotechnology: +0.0%-377.0% Q2'25: -26.3% (vs Q2'24)
-
ROIC Biotechnology: -16.1%— Q2'25: +142.9% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%+0.9% ★ Q2'25: +1.1% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q2'25: -0.10× (vs Q2'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
11.94M
est: 11.36M (+5.1%)
|
19.58M
est: 17.96M (+9.0%)
|
18.45M
est: 16.83M (+9.6%)
|
14.25M
est: 19.10M (-25.4%)
|
20.13M
est: 52.16M (-61.4%)
|
43.95M
est: 40.79M (+7.7%)
|
9.70M
est: 12.13M (-20.0%)
|
1.00M
1.00M – 1.00M
-91.8% YoY
|
10.00M
10.00M – 10.00M
+900.0% YoY
|
20.00M
20.00M – 20.00M
+100.0% YoY
|
20.00M
20.00M – 20.00M
+0.0% YoY
|
| EBITDA |
-39.09M
est: -11.20M (-249.0%)
|
-39.15M
est: -17.71M (-121.0%)
|
-70.13M
est: -16.60M (-322.5%)
|
-60.40M
est: -18.83M (-220.7%)
|
-77.34M
est: -51.43M (-50.4%)
|
-40.85M
est: -40.21M (-1.6%)
|
-35.89M
est: -11.96M (-200.1%)
|
-985.9K
-985.9K – -985.9K
+91.8% YoY
|
-9.86M
-9.86M – -9.86M
-900.0% YoY
|
-19.72M
-19.72M – -19.72M
-100.0% YoY
|
-19.72M
-19.72M – -19.72M
+0.0% YoY
|
| EBIT |
-42.16M
est: -11.34M (-271.7%)
|
-43.30M
est: -17.94M (-141.4%)
|
-74.77M
est: -16.81M (-344.8%)
|
-64.00M
est: -19.07M (-235.6%)
|
-80.90M
est: -52.08M (-55.3%)
|
-43.61M
est: -40.72M (-7.1%)
|
-36.57M
est: -12.11M (-202.0%)
|
-998.5K
-998.5K – -998.5K
+91.8% YoY
|
-9.98M
-9.98M – -9.98M
-900.0% YoY
|
-19.97M
-19.97M – -19.97M
-100.0% YoY
|
-19.97M
-19.97M – -19.97M
+0.0% YoY
|
| Net Income |
-43.04M
est: -282.12M (+84.7%)
|
-44.08M
est: -227.58M (+80.6%)
|
-75.67M
est: -276.93M (+72.7%)
|
-64.92M
est: -133.27M (+51.3%)
|
-81.58M
est: -51.88M (-57.2%)
|
-43.50M
est: -26.50M (-64.2%)
|
-13.84M
est: -41.99M (+67.0%)
|
-27.07M
-27.07M – -27.07M
+35.5% YoY
|
-19.35M
-19.35M – -19.35M
+28.5% YoY
|
-21.25M
-21.25M – -21.25M
-9.8% YoY
|
-26.56M
-26.56M – -26.56M
-25.0% YoY
|
| SGA |
16.72M
est: 10.79M (+54.9%)
|
19.74M
est: 17.06M (+15.7%)
|
19.18M
est: 15.99M (+19.9%)
|
18.76M
est: 18.15M (+3.4%)
|
18.63M
est: 60.28M (-69.1%)
|
20.23M
est: 47.13M (-57.1%)
|
19.75M
est: 14.02M (+40.9%)
|
1.16M
1.16M – 1.16M
-91.8% YoY
|
11.56M
11.56M – 11.56M
+900.0% YoY
|
23.11M
23.11M – 23.11M
+100.0% YoY
|
23.11M
23.11M – 23.11M
+0.0% YoY
|
| EPS |
-24.10
est: -22.50 (-7.1%)
|
-16.93
est: -18.15 (+6.7%)
|
-23.04
est: -22.09 (-4.3%)
|
-9.91
est: -10.63 (+6.8%)
|
-8.63
est: -4.10 (-110.4%)
|
-3.47
est: -2.10 (-65.6%)
|
-1.09
est: -3.32 (+67.2%)
|
-2.14
-2.14 – -2.14
+35.5% YoY
|
-1.53
-1.53 – -1.53
+28.5% YoY
|
-1.68
-1.68 – -1.68
-9.8% YoY
|
-2.10
-2.10 – -2.10
-25.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-69.45M
OE per share TTM
-5.53
Owner's Yield
-465.32%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
63.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
4
Total invested
363.1K
Insider transactions (90d)
0
Beneficial owners (>5%)
37
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Baker Bros. Advisors (GP) LLC | 9.81M | 9.99% | 9.81M | — | 9.81M | — | HC, OO | Delaware | 2024-06-14 | ↗ |
| 2 | Baker Bros. Advisors LP | 9.81M | 9.99% | 9.81M | — | 9.81M | — | IA, PN | Delaware | 2024-06-14 | ↗ |
| 3 | Felix J. Baker | 9.81M | 9.99% | 9.81M | — | 9.81M | — | HC, IN | United States | 2024-06-14 | ↗ |
| 4 | Julian C. Baker | 9.81M | 9.99% | 9.81M | — | 9.81M | — | HC, IN | United States | 2024-06-14 | ↗ |
| 5 | EcoR1 Capital, LLC | 5.72M | 11.00% | — | 5.72M | — | 5.72M | IA, OO | Delaware | 2024-05-31 | ↗ |
| 6 | Oleg Nodelman | 5.72M | 11.00% | — | 5.72M | — | 5.72M | HC, IN | United States | 2024-05-31 | ↗ |
| 7 | Abigail P. Johnson | 5.68M | 11.00% | — | — | 5.68M | — | IN | Delaware | 2022-04-11 | ↗ |
| 8 | FMR LLC | 5.68M | 11.00% | 5.67M | — | 5.68M | — | HC | Delaware | 2022-04-11 | ↗ |
| 9 | Artal Group S.A. | 5.67M | 5.90% | 5.67M | — | 5.67M | — | OO | Bermuda | 2024-07-08 | ↗ |
| 10 | Artal International Management S.A. | 5.67M | 5.90% | 5.67M | — | 5.67M | — | OO | Bermuda | 2024-07-08 | ↗ |
| 11 | Artal International S.C.A. | 5.67M | 5.90% | 5.67M | — | 5.67M | — | OO | Bermuda | 2024-07-08 | ↗ |
| 12 | Invus Public Equities Advisors, LLC | 5.67M | 5.90% | 5.67M | — | 5.67M | — | OO | Bermuda | 2024-07-08 | ↗ |
| 13 | Invus Public Equities, L.P. | 5.67M | 5.90% | 5.67M | — | 5.67M | — | PN | Bermuda | 2024-07-08 | ↗ |
| 14 | Mr. Amaury Wittouck | 5.67M | 5.90% | 5.67M | — | 5.67M | — | IN | Bermuda | 2024-07-08 | ↗ |
| 15 | Stichting Administratiekantoor Westend | 5.67M | 5.90% | 5.67M | — | 5.67M | — | OO | Bermuda | 2024-07-08 | ↗ |
| 16 | Westend S.A. | 5.67M | 5.90% | 5.67M | — | 5.67M | — | OO | Bermuda | 2024-07-08 | ↗ |
| 17 | Knoll Capital Management, LLC | 5.52M | 6.80% | — | — | — | 5.52M | — | USA | 2023-06-20 | ↗ |
| 18 | EcoR1 Capital Fund Qualified, L.P. | 5.39M | 11.00% | — | 5.39M | — | 5.39M | PN | Delaware | 2024-05-31 | ↗ |
| 19 | David Kroin | 5.04M | 9.90% | — | 5.04M | — | — | HC, IN | Delaware | 2022-03-04 | ↗ |
| 20 | Deep Track Biotechnology Master Fund, Ltd. | 5.04M | 9.90% | — | 5.04M | — | — | CO | Delaware | 2022-03-04 | ↗ |
| 21 | Deep Track Capital, LP | 5.04M | 9.90% | — | 5.04M | — | — | IA, OO | Delaware | 2022-03-04 | ↗ |
| 22 | Antoine Papiernik (“Papiernik”) | 3.87M | 13.30% | — | 3.87M | — | 3.87M | IN | French Citizen | 2021-02-02 | ↗ |
| 23 | Denis Lucquin (“Lucquin”) | 3.87M | 13.30% | — | 3.87M | — | 3.87M | IN | French Citizen | 2021-02-02 | ↗ |
| 24 | Graziano Seghezzi (“Seghezzi”) | 3.87M | 13.30% | — | 3.87M | — | 3.87M | IN | Italian Citizen | 2021-02-02 | ↗ |
| 25 | Henrijette Richter (“Richter”) | 3.87M | 13.30% | — | 3.87M | — | 3.87M | IN | Danish Citizen | 2021-02-02 | ↗ |
| 26 | Monique Saulnier (“Saulnier”) | 3.87M | 13.30% | — | 3.87M | — | 3.87M | IN | French Citizen | 2021-02-02 | ↗ |
| 27 | Sofinnova Capital VI FCPR (“SC VI”) | 3.87M | 13.30% | 3.87M | — | 3.87M | — | OO | France | 2021-02-02 | ↗ |
| 28 | Sofinnova Partners SAS (“SP SAS”) | 3.87M | 13.30% | 3.87M | — | 3.87M | — | OO | France | 2021-02-02 | ↗ |
| 29 | Jeremy C. Green | 2.77M | 9.90% | — | 2.77M | — | 2.77M | HC, IN | — | 2022-02-14 | ↗ |
| 30 | Redmile Group, LLC | 2.77M | 9.90% | — | 2.77M | — | 2.77M | IA, OO | — | 2022-02-14 | ↗ |
| 31 | Page 2 of 6 Pages | 2.49M | 11.55% | — | 2.49M | — | 2.49M | OO | — | 2020-02-11 | ↗ |
| 32 | Page 3 of 6 Pages | 2.49M | 11.55% | — | 2.49M | — | 2.49M | OO | — | 2020-02-11 | ↗ |
| 33 | Fynveur Management Sàrl | 599.6K | 2.80% | 599.6K | — | 599.6K | — | OO | Bermuda | 2019-05-03 | ↗ |
| 34 | Fynveur SCA | 599.6K | 2.80% | 599.6K | — | 599.6K | — | OO | Bermuda | 2019-05-03 | ↗ |
| 35 | Artal Treasury Limited | 535.0K | 2.50% | 535.0K | — | 535.0K | — | OO | Bermuda | 2019-05-03 | ↗ |
| 36 | B.V. | 927.00 | 3.10% | — | 927.00 | — | 966.00 | OO | — | 2022-02-11 | ↗ |
| 37 | Coöperatief U.A. | 927.00 | 3.10% | — | 927.00 | — | 966.00 | OO | — | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
4
-22 vs prev Q
New positions
2
Closed positions
23
Increased
3
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ACADIAN ASSET MANAGEMENT LLC | — -28.0K (-100.0%) | — -25.0K (-100.0%) | 0.00% -0.223 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 2 | ADVISOR GROUP HOLDINGS, INC. | — -513.0 (-100.0%) | — -466.0 (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 3 | JBF CAPITAL, INC. | — -347.0K (-100.0%) | — -321.0K (-100.0%) | 0.00% -2.767 pp | 0.00% -0.046 pp | USD— | 2 qtrs SOLD |
| 4 | XTX TOPCO LTD | — -18.1K (-100.0%) | — -16.7K (-100.0%) | 0.00% -0.144 pp | 0.00% -0.001 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
42.8K
Cash buys
—
Cash sales
2.00
Net activity
-42,785
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-19 | Peters Malte | Director / Officer | S-Sale | D | Common Stock | 25,172 | 0.82 | 20.7K | 54,347 | D | ↗ |
| 2025-07-22 | Peters Malte | Director / Officer | S-Sale | D | Common Stock | 29,176 | 0.92 | 26.8K | 79,519 | D | ↗ |
| 2025-07-22 | Coelho Mary Theresa | Director / Officer | S-Sale | D | Common Stock | 13,609 | 0.92 | 12.5K | 56,266 | D | ↗ |
| 2024-07-22 | Peters Malte | Director / Officer | A-Award | A | Common Stock | 108,695 | 0.00 | — | 108,695 | — | ↗ |
| 2024-07-22 | Coelho Mary Theresa | Director / Officer | A-Award | A | Common Stock | 69,875 | 0.00 | — | 69,875 | — | ↗ |
| 2024-07-22 | Cassidy Sean A | Director | A-Award | A | Stock Option (Right to Buy) | 9,800 | 6.44 | 63.1K | 9,800 | — | ↗ |
| 2024-06-17 | van de Winkel Jan | Director | A-Award | A | Stock Option (Right to Buy) | 98,000 | 0.71 | 69.6K | 98,000 | — | ↗ |
| 2024-06-17 | Reilly Timothy P. | Director | A-Award | A | Stock Option (Right to Buy) | 49,000 | 0.71 | 34.8K | 49,000 | — | ↗ |
| 2024-06-17 | Peters Malte | Director | A-Award | A | Stock Option (Right to Buy) | 49,000 | 0.71 | 34.8K | 49,000 | — | ↗ |
| 2024-06-17 | O'Neill Julie | Director | A-Award | A | Stock Option (Right to Buy) | 49,000 | 0.71 | 34.8K | 49,000 | — | ↗ |
| 2024-06-17 | Kaufman David Ross | Director | A-Award | A | Stock Option (Right to Buy) | 49,000 | 0.71 | 34.8K | 49,000 | — | ↗ |
| 2024-06-17 | Coelho Mary Theresa | Director | A-Award | A | Stock Option (Right to Buy) | 49,000 | 0.71 | 34.8K | 49,000 | — | ↗ |
| 2024-04-15 | Winderlich Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.76 | 38.0K | 50,000 | — | ↗ |
| 2024-04-15 | Orlinger Klaus | Officer | A-Award | A | Stock Option (Right to Buy) | 367,300 | 0.76 | 279.1K | 367,300 | — | ↗ |
| 2024-04-15 | Necina Roman | Officer | A-Award | A | Stock Option (Right to Buy) | 367,300 | 0.76 | 279.1K | 367,300 | — | ↗ |
| 2024-04-15 | Kandera Reinhard | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 406,200 | 0.76 | 308.7K | 406,200 | — | ↗ |
| 2024-04-15 | Aldag Jorn | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 971,400 | 0.76 | 738.3K | 971,400 | — | ↗ |
| 2024-04-01 | Winderlich Mark | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-20 | GILEAD SCIENCES, INC. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 18,759,465 | — | ↗ |
| 2023-08-21 | Kandera Reinhard | Director / Officer | P-Purchase | A | Common Stock | 7,000 | 0.73 | 5.1K | 43,092 | — | ↗ |
| 2023-08-16 | Kandera Reinhard | Director / Officer | P-Purchase | A | Common Stock | 8,000 | 0.71 | 5.7K | 36,092 | — | ↗ |
| 2023-07-11 | Aldag Jorn | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.83 | 4.1K | 71,952 | — | ↗ |
| 2023-07-07 | Aldag Jorn | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.81 | 4.1K | 66,952 | — | ↗ |
| 2023-07-05 | Aldag Jorn | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.89 | 4.5K | 61,952 | — | ↗ |
| 2023-07-03 | Aldag Jorn | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.89 | 4.5K | 56,952 | — | ↗ |
| 2023-06-30 | Kandera Reinhard | Director / Officer | P-Purchase | A | Common Stock | 12,000 | 0.88 | 10.6K | 28,092 | — | ↗ |
| 2023-06-09 | van de Winkel Jan | Director | A-Award | A | Stock Option (Right to Buy) | 52,000 | 1.01 | 52.5K | 52,000 | — | ↗ |
| 2023-06-09 | Reilly Timothy P. | Director | A-Award | A | Stock Option (Right to Buy) | 26,000 | 1.01 | 26.3K | 26,000 | — | ↗ |
| 2023-06-09 | Peters Malte | Director | A-Award | A | Stock Option (Right to Buy) | 52,000 | 1.01 | 52.5K | 52,000 | — | ↗ |
| 2023-06-09 | O'Neill Julie | Director | A-Award | A | Stock Option (Right to Buy) | 26,000 | 1.01 | 26.3K | 26,000 | — | ↗ |
| 2023-06-09 | Kaufman David Ross | Director | A-Award | A | Stock Option (Right to Buy) | 26,000 | 1.01 | 26.3K | 26,000 | — | ↗ |
| 2023-06-09 | Coelho Mary Theresa | Director | A-Award | A | Stock Option (Right to Buy) | 52,000 | 1.01 | 52.5K | 52,000 | — | ↗ |
| 2023-04-14 | Schlienger Katia | Officer | A-Award | A | Stock Option (Right to Buy) | 184,000 | 1.00 | 184.0K | 184,000 | — | ↗ |
| 2023-04-14 | Orlinger Klaus | Officer | A-Award | A | Stock Option (Right to Buy) | 194,200 | 1.00 | 194.2K | 194,200 | — | ↗ |
| 2023-04-14 | Necina Roman | Officer | A-Award | A | Stock Option (Right to Buy) | 112,100 | 1.00 | 112.1K | 112,100 | — | ↗ |
| 2023-04-14 | Kandera Reinhard | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 214,800 | 1.00 | 214.8K | 214,800 | — | ↗ |
| 2023-04-14 | Baker Christine D. | Officer | A-Award | A | Stock Option (Right to Buy) | 275,800 | 1.00 | 275.8K | 275,800 | — | ↗ |
| 2023-04-14 | Aldag Jorn | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 513,600 | 1.00 | 513.6K | 513,600 | — | ↗ |
| 2023-04-03 | Coelho Mary Theresa | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-09 | Schlienger Katia | Officer | — | D | Stock Option (Right to Buy) | 17,760 | 1.66 | 29.5K | 0 | — | ↗ |
| 2023-01-01 | Peters Malte | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-30 | van de Winkel Jan | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-30 | Reilly Timothy P. | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-30 | Orlinger Klaus | Officer | A-Award | A | Stock Option (Right to Buy) | 48,350 | 0.00 | — | 48,350 | — | ↗ |
| 2022-06-30 | O'Neill Julie | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-30 | Necina Roman | Officer | A-Award | A | Stock Option (Right to Buy) | 48,350 | 0.00 | — | 48,350 | — | ↗ |
| 2022-06-30 | Matushansky Igor | Officer | A-Award | A | Stock Option (Right to Buy) | 92,950 | 0.00 | — | 92,950 | — | ↗ |
| 2022-06-30 | Kelly Michael Aaron | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-30 | Kaufman David Ross | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-30 | Kandera Reinhard | Officer | A-Award | A | Stock Option (Right to Buy) | 92,950 | 0.00 | — | 92,950 | — | ↗ |
| 2022-06-30 | Baker Christine D. | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-06-30 | Aldag Jorn | Officer | A-Award | A | Stock Option (Right to Buy) | 275,250 | 0.00 | — | 275,250 | — | ↗ |
| 2022-04-19 | Orlinger Klaus | Officer | A-Award | A | Stock Option (Right to Buy) | 48,350 | 0.00 | — | 48,350 | — | ↗ |
| 2022-04-19 | Necina Roman | Officer | A-Award | A | Stock Option (Right to Buy) | 48,350 | 1.66 | 80.3K | 48,350 | — | ↗ |
| 2022-04-19 | Matushansky Igor | Officer | A-Award | A | Stock Option (Right to Buy) | 92,950 | 0.00 | — | 92,950 | — | ↗ |
| 2022-04-19 | Kandera Reinhard | Officer | A-Award | A | Stock Option (Right to Buy) | 92,950 | 0.00 | — | 92,950 | — | ↗ |
| 2022-04-19 | Baker Christine D. | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-04-19 | Aldag Jorn | Officer | A-Award | A | Stock Option (Right to Buy) | 275,250 | 0.00 | — | 275,250 | — | ↗ |
| 2022-04-15 | Reilly Timothy P. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-15 | GILEAD SCIENCES INC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 3,759,465 | — | ↗ |
| 2022-02-01 | Orlinger Klaus | Officer | A-Award | A | Common Stock | 9,188 | 3.00 | 27.6K | 10,404 | — | ↗ |
| 2022-02-01 | Necina Roman | Officer | A-Award | A | Common Stock | 12,892 | 3.00 | 38.7K | 14,876 | — | ↗ |
| 2022-02-01 | Matushansky Igor | Officer | A-Award | A | Stock Option (Right to Buy) | 24,888 | 1.50 | 37.3K | 24,888 | — | ↗ |
| 2022-02-01 | Kandera Reinhard | Director / Officer | A-Award | A | Common Stock | 14,056 | 3.00 | 42.2K | 16,092 | — | ↗ |
| 2022-02-01 | Baker Christine D. | Officer | A-Award | A | Stock Option (Right to Buy) | 22,763 | 1.50 | 34.1K | 22,763 | — | ↗ |
| 2022-02-01 | Aldag Jorn | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 39,853 | 1.50 | 59.8K | 39,853 | — | ↗ |
| 2021-12-21 | Matushansky Igor | Officer | S-Sale | D | Common Stock | 7,440 | 2.49 | 18.5K | 84,104 | — | ↗ |
| 2021-06-01 | van de Winkel Jan | Director | A-Award | A | Stock Option (Right to Buy) | 19,200 | 16.61 | 318.9K | 19,200 | — | ↗ |
| 2021-06-01 | Soria Jean-Charles | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 16.61 | 159.5K | 9,600 | — | ↗ |
| 2021-06-01 | Seghezzi Graziano | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 16.61 | 159.5K | 9,600 | — | ↗ |
| 2021-06-01 | O'Neill Julie | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 16.61 | 159.5K | 9,600 | — | ↗ |
| 2021-06-01 | Lengauer Christoph | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 16.61 | 159.5K | 9,600 | — | ↗ |
| 2021-06-01 | Kelly Michael Aaron | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 16.61 | 159.5K | 9,600 | — | ↗ |
| 2021-06-01 | Kaufman David Ross | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 16.61 | 159.5K | 9,600 | — | ↗ |
| 2021-04-21 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 328,620 | 11.60 | 3.81M | 3,177,574 | — | ↗ |
| 2021-04-19 | Orlinger Klaus | Officer | A-Award | A | Stock Option (Right to Buy) | 26,050 | 12.00 | 312.6K | 26,050 | — | ↗ |
| 2021-04-19 | Necina Roman | Officer | A-Award | A | Stock Option (Right to Buy) | 36,750 | 12.00 | 441.0K | 36,750 | — | ↗ |
| 2021-04-19 | Matushansky Igor | Officer | A-Award | A | Stock Option (Right to Buy) | 95,250 | 12.00 | 1.14M | 95,250 | — | ↗ |
| 2021-04-19 | Kandera Reinhard | Officer | A-Award | A | Stock Option (Right to Buy) | 69,300 | 12.00 | 831.6K | 69,300 | — | ↗ |
| 2021-04-19 | Baker Christine D. | Officer | A-Award | A | Stock Option (Right to Buy) | 49,950 | 12.00 | 599.4K | 49,950 | — | ↗ |
| 2021-04-19 | Aldag Jorn | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 207,600 | 12.00 | 2.49M | 207,600 | — | ↗ |
| 2021-03-29 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 36,829 | 13.67 | 503.6K | 3,506,194 | — | ↗ |
| 2021-03-26 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 35,171 | 13.69 | 481.6K | 3,543,023 | — | ↗ |
| 2021-03-25 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 28,546 | 13.12 | 374.6K | 3,578,194 | — | ↗ |
| 2021-03-24 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 52,690 | 13.70 | 721.6K | 3,606,740 | — | ↗ |
| 2021-03-23 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 40,000 | 13.91 | 556.5K | 3,659,430 | — | ↗ |
| 2021-03-22 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 40,534 | 14.54 | 589.3K | 3,699,430 | — | ↗ |
| 2021-03-19 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 166,230 | 14.60 | 2.43M | 3,739,964 | — | ↗ |
| 2021-03-11 | Baker Christine D. | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,500 | — | ↗ |
| 2020-12-17 | Matushansky Igor | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,965 | 0.10 | 596.50 | 7,669 | — | ↗ |
| 2020-12-16 | Matushansky Igor | Officer | M-Exempt | A | Common Stock | 640 | 0.10 | 64.00 | 56,774 | — | ↗ |
| 2020-12-15 | Soria Jean-Charles | Director | A-Award | A | Stock Option (Right to Buy) | 19,200 | 11.97 | 229.8K | 19,200 | — | ↗ |
| 2020-10-21 | van de Winkel Jan | Director | A-Award | A | Common Stock | 9,153 | 0.00 | — | 9,153 | — | ↗ |
| 2020-10-21 | van Deventer Sander | Director | A-Award | A | Common Stock | 2,485 | 0.00 | — | 2,485 | — | ↗ |
| 2020-10-21 | Seghezzi Graziano | Director | A-Award | A | Common Stock | 4,708 | 0.00 | — | 4,708 | — | ↗ |
| 2020-10-21 | O'Neill Julie | Director | A-Award | A | Common Stock | 4,969 | 0.00 | — | 4,969 | — | ↗ |
| 2020-10-21 | Lengauer Christoph | Director | A-Award | A | Common Stock | 4,603 | 0.00 | — | 4,603 | — | ↗ |
| 2020-10-21 | Kelly Michael Aaron | Director | A-Award | A | Common Stock | 5,754 | 0.00 | — | 5,754 | — | ↗ |
| 2020-10-21 | Kaufman David Ross | Director | A-Award | A | Common Stock | 4,577 | 0.00 | — | 4,577 | — | ↗ |
| 2020-10-16 | Soria Jean-Charles | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-02 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 300 | 10.00 | 3.0K | 3,906,194 | — | ↗ |
| 2020-09-15 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 32,336 | 12.45 | 402.6K | 3,915,755 | — | ↗ |
| 2020-07-20 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 12,483 | 11.94 | 149.1K | 3,948,091 | — | ↗ |
| 2020-07-20 | Orlinger Klaus | Officer | A-Award | A | Common Stock | 1,216 | 0.00 | — | 1,216 | — | ↗ |
| 2020-07-20 | Necina Roman | Officer | A-Award | A | Common Stock | 1,984 | 0.00 | — | 1,984 | — | ↗ |
| 2020-07-20 | Matushansky Igor | Officer | A-Award | A | Common Stock | 2,736 | 0.00 | — | 56,134 | — | ↗ |
| 2020-07-20 | Kandera Reinhard | Director / Officer | A-Award | A | Common Stock | 2,036 | 0.00 | — | 2,036 | — | ↗ |
| 2020-07-20 | Aldag Jorn | Director / Officer | A-Award | A | Common Stock | 4,128 | 0.00 | — | 4,128 | — | ↗ |
| 2020-06-29 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | S-Sale | D | Common Stock | 3,280 | 11.78 | 38.6K | 3,960,574 | — | ↗ |
| 2020-06-18 | van de Winkel Jan | Director | A-Award | A | Stock Option (Right to Buy) | 19,200 | 11.45 | 219.8K | 19,200 | — | ↗ |
| 2020-06-18 | van Deventer Sander | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 11.45 | 109.9K | 9,600 | — | ↗ |
| 2020-06-18 | Seghezzi Graziano | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 11.45 | 109.9K | 9,600 | — | ↗ |
| 2020-06-18 | O'Neill Julie | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 11.45 | 109.9K | 9,600 | — | ↗ |
| 2020-06-18 | Lengauer Christoph | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 11.45 | 109.9K | 9,600 | — | ↗ |
| 2020-06-18 | Kelly Michael Aaron | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 11.45 | 109.9K | 9,600 | — | ↗ |
| 2020-06-18 | Kaufman David Ross | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 11.45 | 109.9K | 9,600 | — | ↗ |
| 2020-04-20 | Orlinger Klaus | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 8.03 | 240.9K | 0 | — | ↗ |
| 2020-04-20 | Necina Roman | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.03 | 401.5K | 0 | — | ↗ |
| 2020-04-20 | Matushansky Igor | Officer | A-Award | A | Stock Option (Right to Buy) | 65,200 | 8.03 | 523.6K | 0 | — | ↗ |
| 2020-04-20 | Kandera Reinhard | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 77,400 | 8.03 | 621.5K | 0 | — | ↗ |
| 2020-04-20 | Aldag Jorn | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 8.03 | 1.61M | 0 | — | ↗ |
| 2020-01-29 | Matushansky Igor | Officer | S-Sale | D | Common Stock | 5,500 | 12.73 | 70.0K | 53,398 | — | ↗ |
| 2020-01-23 | Lilja Anders | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,075 | 0.10 | 407.50 | 0 | — | ↗ |
| 2020-01-21 | Orlinger Klaus | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,789 | 0.10 | 678.90 | 7,741 | — | ↗ |
| 2020-01-16 | Orlinger Klaus | Officer | M-Exempt | D | Stock Option (Right to Buy) | 571 | 0.10 | 57.10 | 14,530 | — | ↗ |
| 2020-01-14 | Orlinger Klaus | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,358 | 0.10 | 735.80 | 0 | — | ↗ |
| 2019-12-19 | Matushansky Igor | Officer | M-Exempt | A | Common Stock | 19,891 | 0.10 | 2.0K | 69,302 | — | ↗ |
| 2019-12-18 | van de Winkel Jan | Director | A-Award | A | Stock Option (Right to Buy) | 28,800 | 9.96 | 286.8K | 28,800 | — | ↗ |
| 2019-12-18 | van Deventer Sander | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 9.96 | 95.6K | 9,600 | — | ↗ |
| 2019-12-18 | Seghezzi Graziano | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 9.96 | 95.6K | 9,600 | — | ↗ |
| 2019-12-18 | O'Neill Julie | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 9.96 | 95.6K | 9,600 | — | ↗ |
| 2019-12-18 | Lengauer Christoph | Director | A-Award | A | Stock Option (Right to Buy) | 9,600 | 9.96 | 95.6K | 9,600 | — | ↗ |
| 2019-12-17 | Matushansky Igor | Officer | M-Exempt | A | Stock Option (Right to Buy) | 26,312 | 0.10 | 2.6K | 46,375 | — | ↗ |
| 2019-12-09 | Necina Roman | Officer | A-Award | A | Stock Option (Right to Buy) | 125,008 | 8.21 | 1.03M | 125,008 | — | ↗ |
| 2019-11-01 | Necina Roman | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-23 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | C-Conversion | D | Series B Preferred Stock | 1,719,189 | 0.00 | — | 0 | — | ↗ |
| 2019-04-23 | Redmile Group, LLC | 10% Owner | C-Conversion | A | Common Stock | 999,322 | 0.00 | — | 999,322 | — | ↗ |
| 2019-04-23 | Forbion Capital Fund II Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Stock | 53,571 | 14.00 | 750.0K | 2,494,173 | — | ↗ |
| 2019-04-23 | BAKER BROS. ADVISORS LP | — | C-Conversion | A | Class A Common Stock | 529,758 | 0.00 | — | 529,758 | — | ↗ |
| 2019-04-17 | van de Winkel Jan | Director | — | D | Stock Option (Right to Buy) | 81,967 | 0.10 | 8.2K | 0 | — | ↗ |
| 2019-04-17 | van Deventer Sander | Director | A-Award | A | Stock Option (Right to Buy) | 19,200 | 14.00 | 268.8K | 19,200 | — | ↗ |
| 2019-04-17 | Seghezzi Graziano | Director | A-Award | A | Stock Option (Right to Buy) | 19,200 | 14.00 | 268.8K | 19,200 | — | ↗ |
| 2019-04-17 | SOFINNOVA CAPITAL VI FCPR | 10% Owner | — | D | Series B Preferred Stock | 1,719,189 | 0.00 | — | 0 | — | ↗ |
| 2019-04-17 | Redmile Group, LLC | 10% Owner | — | I | Series D Redeemable Convertible Preferred Stock | 999,322 | 0.00 | — | 0 | — | ↗ |
| 2019-04-17 | Pinschewer David | Officer | — | D | Stock Option (Right to Buy) | 41,751 | 0.10 | 4.2K | 0 | — | ↗ |
| 2019-04-17 | Orlinger Klaus | Officer | — | D | Stock Option (Right to Buy) | 23,286 | 0.10 | 2.3K | 0 | — | ↗ |
| 2019-04-17 | O'Neill Julie | Director | — | D | Stock Option (Right to Buy) | 12,271 | 10.33 | 126.8K | 0 | — | ↗ |
| 2019-04-17 | Matushansky Igor | Officer | — | D | Common Stock | 0 | 0.00 | — | 28,583 | — | ↗ |
| 2019-04-17 | Lilja Anders | Officer | — | D | Stock Option (Right to Buy) | 23,286 | 0.10 | 2.3K | 0 | — | ↗ |
| 2019-04-17 | Lengauer Christoph | Director | — | D | Stock Option (Right to Buy) | 12,271 | 10.33 | 126.8K | 0 | — | ↗ |
| 2019-04-17 | Kelly Michael Aaron | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-17 | Kaufman David Ross | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-17 | Kandera Reinhard | Director / Officer | — | D | Stock Option (Right to Buy) | 35,022 | 0.10 | 3.5K | 0 | — | ↗ |
| 2019-04-17 | Forbion Capital Fund II Cooperatief U.A. | 10% Owner | — | I | Series C Preferred Stock | 597,497 | 0.00 | — | 0 | — | ↗ |
| 2019-04-17 | BAKER BROS. ADVISORS LP | 10% Owner | — | I | Series C Preferred Stock | 2,905,359 | 0.00 | — | 0 | — | ↗ |
| 2019-04-17 | Aldag Jorn | Director / Officer | — | D | Stock Option (Right to Buy) | 395,852 | 0.10 | 39.6K | 0 | — | ↗ |
| 2008-07-01 | BOYLE TIMOTHY P | Director | A-Award | A | Common Stock | 454,660 | 4.61 | 2.10M | 452,842 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-4.5K
Shares Outstanding
12.52M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Joern Aldag Chief Executive Officer | 567.5K | — | — | 282.1K | 280.9K | — | 1.13M | 24.95% | ↗ |
| 2 | 2023 | Christine Baker Former Chief Operating Officer | 477.0K | — | — | 151.5K | 171.7K | 13.2K | 813.4K | 18.62% | ↗ |
| 3 | 2023 | Reinhard Kandera Chief Financial Officer | 436.0K | — | — | 118.0K | 157.0K | 14.5K | 725.5K | 16.26% | ↗ |
| 4 | 2022 | Joern Aldag Chief Executive Officer | 389.6K | — | — | 701.1K | 159.7K | — | 1.25M | 56.07% | ↗ |
| 5 | 2022 | Christine Baker Former Chief Operating Officer | 394.3K | — | — | 263.1K | 204.1K | 12.2K | 873.6K | 30.12% | ↗ |
| 6 | 2022 | Christine Baker Chief Operating Officer | 394.3K | — | — | 263.1K | 204.1K | 12.2K | 873.6K | 30.12% | ↗ |
| 7 | 2022 | Reinhard Kandera Chief Financial Officer | 343.5K | — | — | 246.9K | 112.7K | 12.1K | 715.2K | 34.52% | ↗ |
| 8 | 2021 | Joern Aldag Chief Executive Officer | 572.3K | — | — | 1.79M | 243.2K | — | 2.61M | 68.70% | ↗ |
| 9 | 2021 | Igor Matushansky Chief Medical Officer | 436.5K | — | — | 821.2K | 149.3K | 11.6K | 1.42M | 57.89% | ↗ |
| 10 | 2021 | Reinhard Kandera Chief Financial Officer | 420.5K | — | — | 597.5K | 143.0K | 14.3K | 1.18M | 50.84% | ↗ |
| 11 | 2020 | Joern Aldag Chief Executive Officer | 495.1K | — | 49.1K | 1.08M | 297.9K | — | 1.92M | 58.78% | ↗ |
| 12 | 2020 | Reinhard Kandera Chief Financial Officer | 373.8K | — | 24.2K | 418.7K | 175.1K | 13.1K | 1.00M | 44.07% | ↗ |
| 13 | 2020 | Igor Matushansky Chief Medical Officer | 399.8K | — | 32.5K | 352.7K | 189.3K | 13.9K | 988.2K | 38.98% | ↗ |
| 14 | 2019 | Joern Aldag Chief Executive Officer | 469.2K | — | — | 5.62M | 281.5K | — | 6.37M | 88.21% | ↗ |
| 15 | 2019 | Reinhard Kandera Chief Financial Officer | 352.2K | — | — | 814.3K | 169.1K | 12.9K | 1.35M | 60.38% | ↗ |
| 16 | 2019 | Igor Matushansky Chief Medical Officer | 393.5K | — | — | 483.7K | 177.1K | 88.4K | 1.14M | 42.33% | ↗ |
| 17 | 2018 | Igor Matushansky Chief Medical Officer | 357.0K | — | — | 279.2K | 158.3K | 11.4K | 805.9K | 34.64% | ↗ |
| 18 | 2018 | Joern Aldag Chief Executive Officer | 361.6K | — | — | — | 180.8K | 5.2K | 547.6K | 0.00% | ↗ |
| 19 | 2018 | Reinhard Kandera Chief Financial Officer | 295.3K | — | — | — | 147.7K | 13.6K | 456.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Malte Peters | Chief Executive Officer, President & Director | 938.3K | — |
| Mary Theresa Coelho | Executive Vice President, Chief Financial Officer & Director | 603.1K | female |
| Daniel D. Pinschewer | Co-Founder & Member of Scientific Advisory Board | — | — |
| Mark Winderlich | Chief Research & Development Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HOOK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
